FDA Accepts Verrica's Resubmission For VP-102 For Contagious Skin Disease

The FDA has accepted Verrica Pharmaceuticals Inc's VRCA resubmitted marketing application seeking approval for VP-102 to treat molluscum contagiosum (molluscum), a common, highly contagious skin disease.

  • The assigned Prescription Drug User Fee Act (PDUFA) goal date is May 24, 2022.
  • In September, the FDA issued a complete response letter for VP-102 after identifying deficiencies at a contract manufacturing organization facility.
  • VP-102 is Verrica's lead product candidate, a proprietary drug-device combination product that contains a controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. 
  • If approved, VP-102 would be the first product approved by the FDA to treat molluscum contagiosum.
  • VP-102 would be marketed in the U.S. under the conditionally accepted brand name, 'Ycanth.'
  • Price Action: VRCA shares closed 12.9% higher at $10.64 during after-hours trading on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!